Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients

Rachdi, Chaima; Damak, R.; Fekih‐Romdhane, Feten; Ouertani, H.; Cheour, Majda

doi:10.1016/j.pcd.2018.09.003

Cited by 12 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following 12 weeks’ treatment with 50mg sertraline, there were significant decreases in weight, body mass index and waist circumference. In contrast to other studies, the reduction in HbA 1c was not significant 9 …”

Section: Specific Evidence For Use In Diabetescontrasting

confidence: 99%

“…In contrast to other studies, the reduction in HbA1c was not significant. 9 The Diabetes and Depression (DAD) trial was a randomised con trolled singleblind trial which assessed the effect of cognitive behav ioural therapy (CBT) vs sertraline in 251 patients with depression and poorly controlled diabetes (mean HbA1c 77mmol/mol). Fiftyone per cent of participants had type 1 diabe tes.…”

Section: Specific Evidence For Use In Diabetesmentioning

confidence: 99%

See 1 more Smart Citation

Sertraline

2022

View full text Add to dashboard Cite

Section: Specific Evidence For Use In Diabetescontrasting

confidence: 99%

Section: Specific Evidence For Use In Diabetesmentioning

confidence: 99%

Sertraline

2022

View full text Add to dashboard Cite

“…SSRI treatment alone could potentially kill two birds with one stone i.e., manage both depressive and diabetic symptoms. One such clinical trial administered patients with comorbid depression and diabetes with Sertraline for 12 weeks and recorded a significant reduction in (a) depressive symptoms (87.9% patients with no symptoms at endpoint), (b) weight, (c) BMI, and (d) nonsignificant but decent reduction in fasting and postprandial plasma glucose and glycosylated hemoglobin levels (Rachdi et al., 2019). Maximum peripheral serotonin storage is in the platelets (Duerschmied et al., 2013), and dysregulated serotonin signaling in platelets is associated with depression (Ziegelstein et al., 2009).…”

Section: Physiological Factors That Play Key Roles In the Comorbiditymentioning

confidence: 99%

Pathophysiology linking depression and type 2 diabetes: Psychotherapy, physical exercise, and fecal microbiome transplantation as damage control

Subba

Sandhir

Singh

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

Diabetes increases the likelihood of developing depression and vice versa. Research on this bidirectional association has somewhat managed to delineate the interplay among implicated physiological processes. Still, further exploration is required in this context. This review addresses the comorbidity by investigating suspected common pathophysiological mechanisms. One such factor is psychological stress which disturbs the hypothalamic–pituitary–adrenal axis causing hormonal imbalance. This includes elevated cortisol levels, a common biomarker of both depression and diabetes. Disrupted insulin signaling drives the hampered neurotransmission of serotonin, dopamine, and norepinephrine. Also, adipokine hormones such as adiponectin, leptin, and resistin and the orexigenic hormone, ghrelin, are involved in both depression and T2DM. This disarray further interferes with physiological processes encompassing sleep, the gut–brain axis, metabolism, and mood stability. Behavioral coping mechanisms, such as unhealthy eating, mediate disturbed glucose homeostasis, and neuroinflammation. This is intricately linked to oxidative stress, redox imbalance, and mitochondrial dysfunction. However, interventions such as psychotherapy, physical exercise, fecal microbiota transplantation, and insulin‐sensitizing agents can help to manage the distressing condition. The possibility of glucagon‐like peptide 1 possessing a therapeutic role has also been discussed. Nonetheless, there stands an urgent need for unraveling new correlating targets and biological markers for efficient treatment.

show abstract

“…Six studies [19][20][21][22][23][24] discussed the effect of antidepressant medications on T2DM diagnosis and prognosis due to their side effect of predisposing to metabolic disorders. Lunghi et al, [19] showed that patients prescribed antidepressant medications had a higher BMI (average 32.6, SD+/-= 6.5) compared with those who did not take them (29.2, SD+/-= 5.7).…”

Section: Part 1-critical Literature Reviewmentioning

confidence: 99%

“…Ivanova et al, [20] described how weight gain linked to both antidiabetic and antidepressant medications are known risk factors in worsening T2DM outcome. Rachdi [21] agreed that antidepressants can have a major metabolic impact and can cause T2DM, suggesting that the use of sertraline as an antidepressant in patients with T2DM may reduce weight gain.…”

Section: Part 1-critical Literature Reviewmentioning

confidence: 99%

A Critical Literature Review and Audit of Real World Data to Inform the Relationship Between Mental Ill-Health and Type-2 Diabetes Favourable Prognosis

Bibi

Wara

Mughal

et al. 2019

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: The aim of this scoping study was to identify gaps in the current literature and understand the T2DM and MIH comorbidity trends in the local population from the West Midlands, UK to inform future studies. Methods: This project was a scoping study of two parts; a critical review and a clinical audit. A thematic approach was used to group studies based on their overall study outcome. The clinical audit data was used to compare the local patient population to the patterns identified in the literature reviewed. Results: The reviewed studies reported a relationship between T2DM control and both depression and anxiety, but did not agree on its significance. The clinical audit of 71 patients diagnosed with T2DM showed that 73% of males presented with poor diabetes control (HbA1c>7) compared to females (46%). Conversely, females exhibited a higher prevalence of MIH (45%) compared to males (31%). Conclusion: From both this audit of the literature and local data, it remains unclear whether mental-ill health is a major driver for medication non-adherence behaviour and uncontrolled diabetes. Further studies are recommended to further understand this comorbidity.

show abstract

Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients

Cited by 12 publications

References 33 publications

Sertraline

Sertraline

Pathophysiology linking depression and type 2 diabetes: Psychotherapy, physical exercise, and fecal microbiome transplantation as damage control

A Critical Literature Review and Audit of Real World Data to Inform the Relationship Between Mental Ill-Health and Type-2 Diabetes Favourable Prognosis

Contact Info

Product

Resources

About